Companies/BeOne Medicines AG

Company profile

BeOne Medicines AG

NASDAQ: ONC · Healthcare · Biotechnology

PublicHQ Basel, PACIK 0001651308Reports USD

#57 of 1,394 Healthcare companies by revenuetop-quartile growth

EA Score

75B+

FH 82DQ 69GM 66SS 80

v0.1 · 65/100 weight · provisional

↑ market scale, Piotroski F · ↓ growth stability, listing tenure

Methodology →

Revenue TTM

$5.7B

Rev growth YoY (TTM)

+37.4%

Net income (FY)

$286.9M

Employees

12,000

Market cap

$31.8B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$5.3B$5.3B2025

Net income$286.9M$286.9M2025

Operating income$447.1M$447.1M2025

Total assets$8.2B$8.2B2025

Liabilities$3.8B$3.8B2025

Equity$4.4B$4.4B2025

Revenue trend

FY2020 – FY2025 · USD

$65.6M

FY20

$91.1M

FY20

$308.9M

FY20

$1.2B

FY22

$1.4B

FY22

$2.5B

FY23

$3.8B

FY24

$5.3B

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Product99%

Collaboration1%

By geography

UNITED STATES56%

CHINA32%

Europe12%

The read

BeOne Medicines AG booked $5.3B in FY2025 revenue, growing 40% year over year — faster than most Healthcare companies we track, at a 5.4% net margin.

Peers · Healthcare

Biogen Inc.85A Moderna, Inc.52D Zoetis Inc.82B+Veeva Systems Inc.86A

Key facts

CEOJohn V. Oyler

SectorHealthcare

IndustryBiotechnology

HeadquartersBasel, PA

ExchangeNASDAQ: ONC

Employees12,000

IPO date2016-02-03

Latest filings

8-K2026-06-26 8-K2026-06-11 8-K2026-05-15 10-Q2026-05-06 8-K2026-05-06 DEF 14A2026-04-28 8-K2026-04-14 10-K2026-02-26

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.